Top Growth Trends in the Chikungunya Market: Key Insights and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the chikungunya market right now?
The market for chikungunya has made significant strides in growth recently. It’s projected to expand from a market value of $0.59 billion in 2024 to $0.65 billion in 2025, boasting a compound annual growth rate (CAGR) of 9.8%. Several factors have contributed to this upward trend during the historical period, including the rise in healthcare spending per individual, a surge in new and recurring infectious diseases, growing levels of disposable income per person, alterations in climate, and heightened consciousness about mosquito-borne illnesses.
How fast Is the chikungunya market expected to grow, and what’s its future value?
In the coming years, strong expansion is anticipated in the chikungunya market, with an estimated growth to $0.93 billion in 2029, signifying a compound annual growth rate (CAGR) of 9.4%. The propelling factors for this growth during the forecast period could be tied to a global surge in clinical trials, an expanding elderly population, an escalating need for vaccines, the rise in state and private sector initiatives, increased government funding, and policies that favor this sector. Notable trends for the forecast period encompass advancements in biotechnological methods for vaccine production, introduction of new vaccine potentials, using CRISPR and AI for innovative solutions, strategic partnerships among pharma companies, and integration of telemedicine services.
Get your chikungunya market report here!
https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report
What are the leading drivers of growth in the chikungunya market?
The surging occurrence of diseases transmitted by mosquitoes is anticipated to fuel the expansion of the chikungunya market. Diseases such as chikungunya, dengue, and zika virus, spread by infected aedes mosquitoes, are presenting substantial health issues worldwide. Factors like climate variations, urban growth, deforestation, accumulation of stagnant water, inadequate measures for vector control, increased global travel, and resistance to insecticides contribute to the escalating worldwide prevalence of these diseases. Therapies for chikungunya play a significant role in aiding those affected by mosquito-borne diseases by reducing symptoms like fever, joint pain, and inflammation, enhancing comfort and mobility, minimizing the likelihood of complications, and facilitating recovery through hydration, pain management, and supportive care. Take for instance the statistics released by the UK Health Security Agency – a government body in the UK – in December 2024. They reported a 201% rise in dengue cases among returning travelers in England, Wales, and Northern Ireland from January to June 2024, from 157 cases during the same timeframe in 2023 to 473. As a result, the escalating worldwide prevalence of diseases transmitted by mosquitoes is spearheading the expansion of the chikungunya market.
What are the key segments defining the chikungunya market?
The chikungunya market covered in this report is segmented –
1) By Type: Antiviral Drugs, Herbal And Complementary Treatments, Supportive Care, Vaccines
2) By Product Form: Liquid Form, Powder, Solid Form
3) By Disease Stage: Acute, Chronic, Post-Infection
4) By Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets
5) By End User: Caregivers, Healthcare Professionals, Patients
Subsegments:
1) By Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors
2) By Herbal And Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine
3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy
4) By Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp
Who are the key players steering the development of the chikungunya market?
Major companies operating in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.
Which trends are expected to transform the chikungunya market?
Big players in the chikungunya industry are orienting their focus towards crafting innovative immunization treatments to augment immunity, deter disease spread, and manage the escalating worldwide health implications of chikungunya virus infiltrations. An example of such a solution is a live attenuated vaccine for chikungunya, a product that utilizes a diluted version of the chikungunya virus to trigger an immune reaction without producing the illness, thus delivering enduring immunity. In November 2023, Valneva SE, a biotech firm headquartered in France, introduced IXCHIQ, a live attenuated vaccine for chikungunya greenlit by the US governance unit, Food and Drug Administration (FDA). This consent was granted under speeded approval based on anti-CHIKV neutralizing antibody scores, with continued approval reliant on the validation of clinical advantage in consequent studies. The FDA awarded Valneva with a Priority Review Voucher (PRV), a resource the firm plans to liquidate to financially support its R&D endeavors. Administered as a one-time muscular injection, Ixchiq comprises a live, less potent strain of the chikungunya virus, which might generate symptoms in recipients mirroring those of chikungunya illness.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21137
Which regions are most influential in expanding the chikungunya market?
North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Arthritis Monoclonal Antibodies Global Market Report 2025
Biosimilar Monoclonal Antibodies Global Market Report 2025
Fertility Services Global Market Report 2025
https://thebusinessresearchcompany.com/report/fertility-services-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
